JP2016520082A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520082A5
JP2016520082A5 JP2016514047A JP2016514047A JP2016520082A5 JP 2016520082 A5 JP2016520082 A5 JP 2016520082A5 JP 2016514047 A JP2016514047 A JP 2016514047A JP 2016514047 A JP2016514047 A JP 2016514047A JP 2016520082 A5 JP2016520082 A5 JP 2016520082A5
Authority
JP
Japan
Prior art keywords
cancer
seq
medicament
medicament according
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016514047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/037911 external-priority patent/WO2014186403A2/en
Publication of JP2016520082A publication Critical patent/JP2016520082A/ja
Publication of JP2016520082A5 publication Critical patent/JP2016520082A5/ja
Withdrawn legal-status Critical Current

Links

JP2016514047A 2013-05-14 2014-05-13 抗ｆｏｌｒ１免疫複合体投与計画 Withdrawn JP2016520082A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361823317P 2013-05-14 2013-05-14
US61/823,317 2013-05-14
US201361828586P 2013-05-29 2013-05-29
US61/828,586 2013-05-29
PCT/US2014/037911 WO2014186403A2 (en) 2013-05-14 2014-05-13 Anti-folr1 immunoconjugate dosing regimens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018143909A Division JP2018197249A (ja) 2013-05-14 2018-07-31 抗ｆｏｌｒ１免疫複合体投与計画

Publications (2)

Publication Number Publication Date
JP2016520082A JP2016520082A (ja) 2016-07-11
JP2016520082A5 true JP2016520082A5 (enExample) 2017-06-29

Family

ID=51898993

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016514047A Withdrawn JP2016520082A (ja) 2013-05-14 2014-05-13 抗ｆｏｌｒ１免疫複合体投与計画
JP2018143909A Withdrawn JP2018197249A (ja) 2013-05-14 2018-07-31 抗ｆｏｌｒ１免疫複合体投与計画
JP2021062774A Withdrawn JP2021102648A (ja) 2013-05-14 2021-04-01 抗ｆｏｌｒ１免疫複合体投与計画
JP2023145920A Pending JP2023162436A (ja) 2013-05-14 2023-09-08 抗ｆｏｌｒ１免疫複合体投与計画

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018143909A Withdrawn JP2018197249A (ja) 2013-05-14 2018-07-31 抗ｆｏｌｒ１免疫複合体投与計画
JP2021062774A Withdrawn JP2021102648A (ja) 2013-05-14 2021-04-01 抗ｆｏｌｒ１免疫複合体投与計画
JP2023145920A Pending JP2023162436A (ja) 2013-05-14 2023-09-08 抗ｆｏｌｒ１免疫複合体投与計画

Country Status (14)

Country Link
US (5) US20140363451A1 (enExample)
EP (1) EP2997044A4 (enExample)
JP (4) JP2016520082A (enExample)
KR (4) KR20230066648A (enExample)
CN (2) CN105308072A (enExample)
AU (3) AU2014265587A1 (enExample)
BR (1) BR112015028244A2 (enExample)
CA (1) CA2911499A1 (enExample)
HK (1) HK1222340A1 (enExample)
IL (1) IL268180A (enExample)
MX (2) MX2015015735A (enExample)
RU (1) RU2015149285A (enExample)
SG (2) SG10201701096UA (enExample)
WO (1) WO2014186403A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI672318B (zh) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
CN114441757A (zh) 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
PL2890717T3 (pl) 2012-08-31 2020-08-10 Immunogen, Inc. Testy i zestawy diagnostyczne do wykrywania receptora folianu
CN105814079B (zh) 2013-08-30 2021-02-09 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
MY174670A (en) * 2013-10-08 2020-05-06 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
AU2017308159B2 (en) 2016-08-12 2023-08-10 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
KR20200051802A (ko) 2017-09-18 2020-05-13 서트로 바이오파마, 인크. 항-엽산 수용체 알파 항체 접합체 및 이의 용도
WO2019157125A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated methotrexate and uses thereof
EP3749319A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES
EP3749316A4 (en) 2018-02-07 2021-10-27 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF
EP3749312A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
JP7487107B2 (ja) 2018-02-07 2024-05-20 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化葉酸代謝拮抗薬およびその使用
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
CN111954531A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化培美曲塞及其用途
CN111954530A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 γ聚谷氨酸化培美曲塞及其用途
CA3090384A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
CA3090391A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
WO2019160736A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
WO2019160733A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
CA3117493A1 (en) * 2018-10-30 2020-05-07 Immunogen, Inc. Methods of treatment using anti-cd123 immunoconjugates
MA55818A (fr) 2019-04-29 2022-03-16 Immunogen Inc Anticorps et immunoconjugués de fr-alpha biparatopique
CN112794911B (zh) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 人源化抗叶酸受体1抗体及其应用
WO2023116911A1 (zh) * 2021-12-24 2023-06-29 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
WO2025036307A1 (zh) * 2023-08-11 2025-02-20 百奥泰生物制药股份有限公司 抗frα抗体药物偶联物在治疗疾病中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
WO2004082463A2 (en) * 2003-03-17 2004-09-30 Medical College Of Ohio Folate receptor gene modulation for cancer diagnosis and therapy
AU2005214331B2 (en) * 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
BR112012009250A2 (pt) * 2009-10-21 2017-06-20 Immunogen Inc composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma
TWI672318B (zh) * 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
CN114441757A (zh) * 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
WO2012138749A1 (en) * 2011-04-04 2012-10-11 Immunogen, Inc. Methods for decreasing ocular toxicity of antibody drug conjugates
MY174670A (en) * 2013-10-08 2020-05-06 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
KR102700777B1 (ko) * 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
MA55818A (fr) * 2019-04-29 2022-03-16 Immunogen Inc Anticorps et immunoconjugués de fr-alpha biparatopique

Similar Documents

Publication Publication Date Title
JP2016520082A5 (enExample)
RU2015149285A (ru) Схемы дозирования иммуноконъюгата anti-folr1
TWI596116B (zh) 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合
JP2020508317A5 (enExample)
JP2018527383A5 (enExample)
JP2018070648A5 (enExample)
RU2018111205A (ru) Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
JP2021059564A (ja) 癌治療のための併用療法
JP2022058802A5 (enExample)
JP2020534250A5 (enExample)
JP2016530323A5 (enExample)
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP2016534039A5 (enExample)
JP2013520442A5 (enExample)
JP2017533912A5 (enExample)
JP2016509582A5 (enExample)
JP2015532292A5 (enExample)
JP2014114288A5 (enExample)
JP2012102122A5 (enExample)
JP2017535246A5 (enExample)
HRP20192140T1 (hr) Režimi doziranja anti-folr1 imunokonjugata
JP2018512402A5 (enExample)
CN114340679A (zh) 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物
CN109663130B (zh) Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
JPWO2022270524A5 (enExample)